A simple validated scale to measure urgency
A simple validated scale to measure urgency
复制标题
DOI：
10.1016/j.juro.2007.10.075
复制
发表时间：
2008-03-01
影响因子：
6.6
通讯作者：
Malone-Lee, James
中科院分区：
文献类型：
--
作者：
Al-Buheissi, Salah;Khasriya, Rajvinder;Malone-Lee, James
目的：我们验证了一个简单的规模来衡量urinity.Materials和方法：新的10项规模进行了验证，使用数据从实验中使用单组重复测量设计。共475例患者，包括411例女性和64例男性，平均年龄为57.3岁，诊断为膀胱过度活动症，接受膀胱再训练方案和抗毒蕈碱剂（每晚10 mg奥昔布宁控释或每晚4 mg托特罗定缓释）治疗。在每次访视时，通过量表记录患者的急迫症状。报告的平均每日频率和尿失禁发作也被记录。在对症状不满意的患者中，130例患者在处方中添加了每晚25 mg丙咪嗪，130例患者的治疗改为每晚10 mg索利那新。通过比较尿急量表与尿频和尿失禁量表的结构效度，（斯皮尔曼等级相关系数分别为r = 0.38，p < 0.001和r = 0.15，p < 0.001）。内部一致性显示Cronbach's alpha = 0.83。在30名患者中确定了重测信度，在58名患者中确定了观察者间信度（Pearson's r = 0.99，p < 0.001和r = 0.99，p < 0.001）。在130例患者的丙咪嗪添加研究中，内部反应性显示标准化反应平均值为0.6（p < 0.001），在130例患者的索利那新交换研究中，内部反应性显示标准化反应平均值为0.69，而外部反应性显示标准化反应平均值为0.69（p <0.001）。标准化反应平均值为0.69（每个p < 0.001）。这种新的尺度可能被证明是有用的测量药物之间的疗效差异和监测膀胱过度活动症患者的治疗反应。现在必须在一个适当的双盲、随机、对照试验中进行测试。
Purpose: We validated a simple scale to measure urinary urgency.Materials and Methods: The new 10-item scale was validated using data from experiments using a single group repeated measure design. A total of 475 patients, including 411 females and 64 males, with a mean age of 57.3 years who had been diagnosed with overactive bladder were treated with a bladder retraining regimen and antimuscarinic agent (10 mg oxybutynin controlled release per night or 4 mg tolterodine slow release per night). At each visit patient urge symptoms were recorded by the scale. Reported average daily frequency and incontinence episodes were also recorded. Of patients who were not satisfied with the symptoms 130 had 25 mg imipramine per night added to their prescription and in 130 treatment was changed to 10 mg solifenacin per night.Results: Construct validity was tested by comparing the urgency scale to frequency and to incontinence (Spearman's rank correlation coefficient r = 0.38, p < 0.001 and r = 0.15, p < 0.001, respectively). Internal consistency showed Cronbach's alpha = 0.83. Test-retest reliability was determined in 30 patients and interobserver reliability was determined in 58 (Pearson's r = 0.99, p < 0.001 and r = 0.99, p < 0.001, respectively). Internal responsiveness in the imipramine add-on study in 130 patients showed a standardized response mean of 0.6 (p < 0.001) and in the solifenacin swap study in 130 it showed a standardized response mean of 0.69, while external responsiveness showed a. standardized response mean of 0.69 (each p < 0.001).Conclusions: This scale succeeded in all validation studies. This new scale may prove useful for measuring between-drug differences in efficacy and for monitoring treatment responses in patients with overactive bladder. It now must be tested in a proper double-blind, randomized, controlled trial.